<DOC>
	<DOCNO>NCT02977065</DOCNO>
	<brief_summary>A multicenter , double-blind , parallel-group , active-controlled , dose-ranging study ass safety efficacy novel cholesteryl ester transfer protein ( CETP ) inhibitor CKD-519 combination atorvastatin rosuvastatin subject dyslipidemia .</brief_summary>
	<brief_title>To Assess Safety , Efficacy Tolerability CKD-519 , Administered With HMG-CoA Reductase Inhibitors</brief_title>
	<detailed_description>The purpose study assess safety , efficacy , tolerability CKD-519 , administer HMG-CoA reductase inhibitor subject dyslipidemia</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>1 . Age 18 80 year . 2 . Dyslipidemia LDLC At screen untreated : 100 190 mg/dL At screen treated statin lipidlowering drug : 100 170 mg/dL At start doubleblind treatment : 100 190 mg/dL . 3 . HDLC &lt; 45 mg/dL ( male ) &lt; 50 mg/dL ( female ) . 4 . Fasting TG &lt; 400 mg/dL . 5 . Presence follow condition permit mandatory , discretion investigator : Treated stable coronary heart disease without acute event past 3 month stable , stateoftheart medication . Treated stable carotid artery disease peripheral arterial disease stable , standard medication past 3 month Treated stable Type 2 diabetes mellitus glycosylated hemoglobin ( HbA1c ) â‰¤9.5 % . 6 . Willing able sign inform consent form ( ICF ) . 1 . Chronic heart failure define New York Heart Association class III IV . 2 . Uncontrolled cardiac arrhythmia . 3 . Myocardial infarction , percutaneous coronary intervention , coronary artery bypass graft , unstable angina past 3 month Visit 1 . 4 . Stroke transient ischemic attack within 3 month Visit 1 . 5 . Uncontrolled hypertension . 6 . Clinically significant laboratory abnormality Aspartate aminotransferase alanine aminotransferase &gt; 2 time upper limit normal range Bilirubin &gt; 1.5 time upper limit normal range Creatine kinase &gt; 2 time upper limit normal range . 7 . Any active nephropathy estimate glomerular filtration rate &lt; 60 mL/min/1.73m2 kidney dialysis . 8 . Poorly control ( thyroidstimulating hormone [ TSH ] &gt; 2 time upper limit normal ) hyperthyroidism . 9 . Homozygous familial hypercholesterolemia . 10 . Intolerance hypersensitivity atorvastatin rosuvastatin . 11 . Prior treatment CETP inhibitor . 12 . Positive human immunodeficiency virus ( HIV ) positive , hepatitis B hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Dyslipidemia</keyword>
	<keyword>CETP Inhibitors</keyword>
	<keyword>Hyperlipidemia</keyword>
</DOC>